Publication | Closed Access
A Phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas
72
Citations
16
References
1999
Year
The cumulative MTD for carboplatin is 1540 mg/m(2) when administered concomitantly with involved field, hyperfractionated radiotherapy in a twice-weekly schedule for 7 weeks. Subsequent Phase II and III clinical trials can be conducted safely at this level.
| Year | Citations | |
|---|---|---|
Page 1
Page 1